3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Recruiting
2
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
1330
Breast Neoplasms
686
Carcinoma, Non-Small-Cell Lung
543
Neoplasm Metastasis
436
Lymphoma
435
Leukemia, Myeloid, Acute
432
Melanoma
402
Prostatic Neoplasms
380
Multiple Myeloma
364
Lymphoma, Non-Hodgkin
355
Ovarian Neoplasms
343
Colorectal Neoplasms
333
Precursor Cell Lymphoblastic Leukemia-Lymphoma
328
Pancreatic Neoplasms
328
Leukemia, Lymphocytic, Chronic, B-Cell
323
Leukemia
282
Lung Neoplasms
275
Glioblastoma
266
Unspecified Adult Solid Tumor, Protocol Specific
257
Recurrence
252
Lymphoma, Follicular
248
Lymphoma, Large B-Cell, Diffuse
245
Brain Neoplasms
232
Lymphoma, Mantle-Cell
210
Carcinoma, Renal Cell
193
Hodgkin Disease
192
Head and Neck Neoplasms
192
Myelodysplastic Syndromes
187
Burkitt Lymphoma
172
Glioma
171
Interventions
ficlatuzumab
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
Blood Protein Disorders
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled